ArticleJournal of bacteriology2001
Growth-phase-dependent expression of the cyclopeptide antibiotic microcin J25.
Article in Journal of bacteriology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 56 citations in OpenAlex.
- Decoding the Microcin J25 Biosynthetic Cluster: Modulation of theInternational journal of molecular sciences · 2026Article
- Shared structural mechanisms of alternating access between the secondary peptide transporter SbmA and ABC transporters.Nature communications · 2026Article
- Decoupling growth phase dependency and metal ion inhibition: A dual engineering strategy for the high-yield biosynthesis of microcin J25 inEngineering microbiology · 2025Article
- Influence of PepF peptidase and sporulation on microcin J25 production inMicrobiology spectrum · 2024Article
- Mcc1229, an Stx2a-Amplifying Microcin, Is ProducedInfection and immunity · 2022Article
- Biosynthetic Microcin J25 Exerts Strong Antibacterial, Anti-Inflammatory Activities, Low Cytotoxicity Without Increasing Drug-Resistance to Bacteria Target.Frontiers in immunology · 2022Article
- Lasso Peptides: Heterologous Production and Potential Medical Application.Frontiers in bioengineering and biotechnology · 2020Review
- Synthesis of a Peptide Derivative of MicrocinJ25 and Evaluation of Antibacterial and Biological Activities.Iranian journal of pharmaceutical research : IJPR · 2019Article
- Isolation and Selection of Potential Probiotic Bacteria from the Pig Gastrointestinal Tract.Probiotics and antimicrobial proteins · 2018Article
- An orthogonal system for heterologous expression of actinobacterial lasso peptides in Streptomyces hosts.Scientific reports · 2018Article
- Antimicrobial Probiotics Reduce Salmonella enterica in Turkey Gastrointestinal Tracts.Scientific reports · 2017Article
- The therapeutic applications of antimicrobial peptides (AMPs): a patent review.Journal of microbiology (Seoul, Korea) · 2017Review
- Isolation and characterization of diverse antimicrobial lipopeptides produced by Citrobacter and Enterobacter.BMC microbiology · 2013Article
- Identification and characterization of microcin S, a new antibacterial peptide produced by probiotic Escherichia coli G3/10.PloS one · 2012Article
- Sensitization of microcin J25-resistant strains by a membrane-permeabilizing peptide.Applied and environmental microbiology · 2010Article
- Protective action of ppGpp in microcin J25-sensitive strains.Journal of bacteriology · 2008Article
- Structure-activity analysis of microcinJ25: distinct parts of the threaded lasso molecule are responsible for interaction with bacterial RNA polymerase.Journal of bacteriology · 2005Article
- Stationary phase-like properties of the bacteriophage lambda Rex exclusion phenotype.Molecular genetics and genomics : MGG · 2003Article
- Escherichia coli RNA polymerase is the target of the cyclopeptide antibiotic microcin J25.Journal of bacteriology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microcin J25 is a 2,107-Da, plasmid-encoded, cyclopeptide antibiotic produced by Escherichia coli. We have isolated lacZ fusions to mcjA (encoding the 58-amino-acid microcin precursor) and mcjB and mcjC (which are required for microcin maturation), and the regulation of these fusions was used to identify factors that control the expression of these genes. The mcjA gene was found to be dramatically induced as cells entered the stationary phase. Expression of mcjA could be induced by resuspending uninduced exponential-phase cells in spent supernatant obtained from an early-stationary-phase culture. Induction of mcjA expression was not dependent on high cell density, pH changes, anaerobiosis, or the buildup of some inducer. A starvation for carbon and inorganic phosphate induced mcjA expression, while under nitrogen limitation there was no induction at all. These results taken together suggest that stationary-phase induction of mcjA is triggered by nutrient depletion. The mcjB and mcjC genes were also regulated by the growth phase of the culture, but in contrast to mcjA, they showed substantial expression already during exponential growth. Induction of the microcin genes was demonstrated to be independent of RpoS, the cyclic AMP-Crp complex, OmpR, and H-NS. Instead, we found that the growth-phase-dependent expression of mcjA, mcjB, and mcjC may be explained by the concerted action of the positively acting transition state regulators ppGpp, Lrp, and integration host factor. Measurements of microcin J25 production by strains defective in these global regulators showed a good correlation with the reduced expression of the fusions in such mutant backgrounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.